ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1959

Low Fracture Incidence Is Maintained in Postmenopausal Women ≥75 Years with Osteoporosis with Long-Term Denosumab Treatment

Socrates Papapoulos1, Michael McClung2, Nathalie Franchimont3, Jonathan D. Adachi4, Henry G. Bone5, Claude-Laurent Benhamou6, Jordi Farrerons7, JC Gallagher8, Johan Halse9, Kurt Lippuner10, Salvatore Minisola11, Ove Törring12, Nadia Daizadeh3, Andrea Wang3, Rachel B. Wagman3 and Steven Boonen13, 1Leiden University Medical Center, Leiden, Netherlands, 2Oregon Osteoporosis Center, Portland, OR, 3Amgen Inc., Thousand Oaks, CA, 4St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5Michigan Bone and Mineral Clinic, Detroit, MI, 6Centre Hospitalier Régional d'Orléans, Orleans, France, 7Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 8Creighton University Medical Center, Omaha, NE, 9Osteoporoseklinikken, Oslo, Norway, 10Bern University Hospital, Bern, Switzerland, 11Sapienza, Università di Roma, Rome, Italy, 12Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, 13Leuven University, Leuven, Belgium

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: bone density and osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: In the pivotal fracture trial, FREEDOM, denosumab increased bone mineral density (BMD) and reduced the incidence of new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis (Cummings SR et al, NEJM 2009). Denosumab reduced the risk of hip fracture in high-risk subgroups, including a 62% reduction in patients ≥75 years old (Boonen S et al, JCEM 2011). The effects of long-term denosumab treatment up to 10 years are being evaluated in the FREEDOM extension study. As fracture incidence increases with age, and in particular, hip fracture in women ≥75, we have further characterized the fracture incidence and BMD gains in women ≥75 who have been treated with denosumab for a total of 6 years.

Methods: During the extension, each woman has received 60 mg denosumab every 6 months and supplemental calcium and vitamin D daily. We evaluated the fracture incidence and BMD gains in women who completed 6 years of denosumab treatment (overall long-term group) and in the subset of these women who were ≥75 at FREEDOM baseline (higher-risk group).

Results: The FREEDOM baseline characteristics for the overall long-term denosumab group (N=2343) and the higher-risk group (N=662) were similar except that those subjects in the higher-risk group were older (mean age: 72 years for overall and 78 years for higher-risk), and had a lower mean total hip BMD T-score (–1.9 for overall and –2.1 for higher-risk). Despite the increase in age of the subjects, denosumab treatment during years 4 to 6 continued to be associated with a low incidence of new vertebral, nonvertebral, and hip fractures. Furthermore, the incidence of fractures in the higher-risk group during years 4 to 6 was similar to what was originally observed in years 1 to 3 in women ≥75 treated with denosumab (Figure). BMD progressively increased over 6 years at the lumbar spine and total hip and was similar in women ≥75 compared with women in the overall long-term group. Despite advanced age, adverse events (AEs) and serious AEs in the higher-risk group in the extension were similar to the higher-risk group from FREEDOM, and these events did not increase over time with denosumab treatment.  

Conclusion: Patients aged ≥75 are at higher risk of fracture than younger patients. Denosumab is a therapeutic option for the women ≥75 in whom the high risk of hip fracture is of particular concern. These results amplify the robust and consistent anti-fracture efficacy and safety profile of continued denosumab treatment over 6 years.


Disclosure:

S. Papapoulos,

Amgen Inc., Merck Co., Novartis, Eli Lilly, GSK,

5;

M. McClung,

Amgen Inc., Merck,

2,

Amgen Inc., Lilly, Merck, Novartis,

5,

Amgen Inc., Lilly, Novartis, Warner-Chilcott,

8;

N. Franchimont,

Amgen Inc., Biogenidec,

1,

Amgen Inc., Biogenidec,

3;

J. D. Adachi,

Amgen, Eli Lilly, GSK, Merck, Novartis, Procter & Gamble, Roche, Sanofi Aventis,

2,

Amgen, Eli Lilly, GSK, Merck, Novartis, Procter & Gamble, Roche, Sanofi Aventis, Warner Chilcott,

5,

Amgen, Eli Lilly, GSK, Merck, Novartis, Procter & Gamble, Roche, Sanofi Aventis, Warner Chilcott,

8;

H. G. Bone,

Amgen Inc.,

2,

Amgen Inc., Merck, Zelos, Tarsa, GSK,

5,

Amgen Inc. ,

8;

C. L. Benhamou,

Amgen Inc., Novartis, MSD, Servier, Roche, Lilly,

2,

Amgen Inc., MSD, Servier, Novartis ,

8;

J. Farrerons,
None;

J. Gallagher,

Amgen Inc.,

2;

J. Halse,

Amgen Inc.,

8;

K. Lippuner,

Amgen Inc., Eli Lilly ,

5;

S. Minisola,

Roche, GSK, Novartis, Nycomed, Sanofi-Aventis, Sigma Tau, Merck Sharpe, Amgen Inc., Chiesi Parmaceutica, ,

8,

Merck Sharp,

5;

O. Törring,

Amgen Inc., Nycomed Takeda,

5,

Amgen Inc., Nycomed Takeda,

8;

N. Daizadeh,

Amgen Inc.,

1,

Amgen Inc.,

3;

A. Wang,

Amgen Inc.,

3,

Amgen Inc.,

1;

R. B. Wagman,

Amgen Inc.,

1,

Amgen Inc.,

3;

S. Boonen,

Amgen Inc.,

2,

Amgen Inc.,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-fracture-incidence-is-maintained-in-postmenopausal-women-%e2%89%a575-years-with-osteoporosis-with-long-term-denosumab-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology